Payment overview · 2025
General Payments
$1,109.48
58 reported records · 18 companies
Healthcare provider profile · identity verified
James Edward Newby, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · NORFOLK, VA · NPI 1265524813
Verified facts
What the public records show
CMS Open Payments records show James Edward Newby, M.D. received $1,109.48 in general payments during 2025 across 58 reported records.
AstraZeneca Pharmaceuticals LP accounted for 30.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 166 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $336.83 | 30.4% | 18 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $111.55 | 10.1% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $81.90 | 7.4% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $67.49 | 6.1% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $64.67 | 5.8% | 4 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$63.74 | 5.8% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $55.58 | 5.0% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $47.09 | 4.2% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $45.13 | 4.1% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $43.46 | 3.9% | 2 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $37.52 | 3.4% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $28.99 | 2.6% | 2 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $27.10 | 2.4% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $25.62 | 2.3% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $22.18 | 2.0% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $19.67 | 1.8% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $15.96 | 1.4% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $15.00 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,109.48 | 58 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $159.27 | 9 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $144.23 | 7 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $111.55 | 6 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $93.79 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $67.49 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $67.10 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $64.67 | 4 | 2025 |
Source payment records
|
|||||
| INPEN SMART INSULIN DELIVERY SYSTEM Normalized: inpen smart insulin delivery system |
Device | Medtronic, Inc. | $63.74 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $55.58 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $54.44 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $47.09 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $45.52 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $45.13 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $43.46 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $42.57 | 2 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $37.52 | 2 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $37.52 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $28.99 | 2 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $27.10 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $25.62 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $22.18 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $22.18 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $19.67 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $19.15 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $15.96 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $15.00 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.80 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.54 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 166 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 97 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 71 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 103 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
42 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
97 | 19 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
71 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
71 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
103 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
166 | 35 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 676 | 193 |
| Amlodipine Besylate | Amlodipine Besylate | 523 | 155 |
| Simvastatin | Simvastatin | 296 | 86 |
| Losartan Potassium | Losartan Potassium | 288 | 85 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 235 | 62 |
| Omeprazole | Omeprazole | 234 | 65 |
| Furosemide | Furosemide | 216 | 64 |
| Tamsulosin Hcl | Tamsulosin Hcl | 208 | 58 |
| Hydrochlorothiazide | Hydrochlorothiazide | 187 | 57 |
| Gabapentin | Gabapentin | 170 | 46 |
| Eliquis | Apixaban | 166 | 35 |
| Allopurinol | Allopurinol | 164 | 35 |
| Metformin Hcl Er | Metformin Hcl | 158 | 43 |
| Metformin Hcl | Metformin Hcl | 150 | 48 |
| Lisinopril | Lisinopril | 143 | 44 |
| Nifedipine Er | Nifedipine | 137 | 44 |
| Levothyroxine Sodium | Levothyroxine Sodium | 129 | 42 |
| Clopidogrel | Clopidogrel Bisulfate | 119 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 113 | 36 |
| Carvedilol | Carvedilol | 109 | 34 |
| Potassium Chloride | Potassium Chloride | 106 | 30 |
| Lovastatin | Lovastatin | 105 | 28 |
| Ozempic | Semaglutide | 103 | 16 |
| Farxiga | Dapagliflozin Propanediol | 97 | 19 |
| Glipizide Er | Glipizide | 92 | 23 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 91 | 28 |
| Metoprolol Succinate | Metoprolol Succinate | 91 | 29 |
| Naproxen | Naproxen | 89 | 35 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 87 | 30 |
| Montelukast Sodium | Montelukast Sodium | 83 | 21 |
| Valsartan | Valsartan | 77 | 25 |
| Ibuprofen | Ibuprofen | 75 | 30 |
| Ezetimibe | Ezetimibe | 73 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 71 | 22 |
| Jardiance | Empagliflozin | 71 | 16 |
| Pregabalin | Pregabalin | 69 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 69 | 28 |
| Pantoprazole Sodium | Pantoprazole Sodium | 68 | 20 |
| Colchicine | Colchicine | 66 | 18 |
| Donepezil Hcl | Donepezil Hcl | 66 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 66 | 18 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 63 | 14 |
| Tramadol Hcl | Tramadol Hcl | 63 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 62 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 61 | 20 |
| Pioglitazone Hcl | Pioglitazone Hcl | 61 | 17 |
| Verapamil Er | Verapamil Hcl | 59 | 17 |
| Spironolactone | Spironolactone | 53 | 13 |
| Glipizide | Glipizide | 50 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 49 | 19 |
| Irbesartan | Irbesartan | 45 | 14 |
| Meclizine Hcl | Meclizine Hcl | 45 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 45 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 44 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 43 | 16 |
| Levetiracetam | Levetiracetam | 43 | suppressed |
| Xarelto | Rivaroxaban | 43 | suppressed |
| Linzess | Linaclotide | 42 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 39 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 38 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 38 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 37 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 36 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 36 | suppressed |
| Famotidine | Famotidine | 35 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 34 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 34 | 12 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 34 | suppressed |
| Finasteride | Finasteride | 33 | 11 |
| Trazodone Hcl | Trazodone Hcl | 32 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 31 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 31 | suppressed |
| Baclofen | Baclofen | 30 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 29 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 29 | suppressed |
| Meloxicam | Meloxicam | 29 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 28 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 28 | suppressed |
| Fenofibrate | Fenofibrate | 28 | suppressed |
| Omnipod Dash Pods (Gen 4) | Insulin Pump Cart,cont Inf,bt | 28 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 28 | suppressed |
| Trulicity | Dulaglutide | 28 | suppressed |
| Atenolol | Atenolol | 27 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 27 | 16 |
| Labetalol Hcl | Labetalol Hcl | 27 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 26 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 26 | 13 |
| Clonidine Hcl | Clonidine Hcl | 25 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 24 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 24 | 12 |
| Olanzapine | Olanzapine | 24 | suppressed |
| Rybelsus | Semaglutide | 24 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 24 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 23 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 23 | suppressed |
| Novolog | Insulin Aspart | 23 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 23 | suppressed |
| Lorazepam | Lorazepam | 22 | suppressed |
| Methocarbamol | Methocarbamol | 22 | 11 |
| Alprazolam | Alprazolam | 21 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 21 | suppressed |
| Bumetanide | Bumetanide | 21 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 21 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 21 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 17 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 19 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 19 | suppressed |
| Cephalexin | Cephalexin | 18 | 15 |
| Methimazole | Methimazole | 18 | suppressed |
| Prednisone | Prednisone | 18 | 15 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Carbamazepine | Carbamazepine | 17 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Risperdal Consta | Risperidone Microspheres | 17 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 15 | suppressed |
| Glimepiride | Glimepiride | 15 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 15 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 14 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Verapamil Sr | Verapamil Hcl | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 11 | suppressed |
| Felodipine Er | Felodipine | 11 | suppressed |
| Humalog | Insulin Lispro | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,109.48 · 58 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, CAPVAXIVE, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, Fluad, Flucelvax, INPEN SMART INSULIN DELIVERY SYSTEM, JARDIANCE, Kerendia, Korlym, MOUNJARO, NURTEC ODT, OTEZLA, Omnipod, Ozempic, PAXLOVID, QULIPTA, REPATHA, Rybelsus, UBRELVY, Wegovy, YUPELRI, ZEPBOUND, ZORYVE | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error